{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T08:29:08Z","timestamp":1768120148886,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00210-019-01764-6","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T05:23:32Z","timestamp":1578029012000},"page":"1549-1558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression"],"prefix":"10.1007","volume":"393","author":[{"given":"Zhao","family":"Jingjing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cao","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Yapeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Weimin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Chunluan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"1764_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"C Bertrand","year":"2002","unstructured":"Bertrand C, Eric L, Josette B, Raoul H, Herv\u00e9 T, Reda B, Pierre M, Eric VDN, Gilles S, Philippe G (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235","journal-title":"N Engl J Med"},{"key":"1764_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2014-04-568188","volume":"125","author":"M Blonska","year":"2015","unstructured":"Blonska M, Zhu Y, Chuang HH, You MJ, Kunkalla K, Vega F, Lin X (2015) Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 125:981\u2013991","journal-title":"Blood"},{"key":"1764_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/onc.2013.56","volume":"33","author":"K Cante-Barrett","year":"2014","unstructured":"Cante-Barrett K, Pieters R, Meijerink JP (2014) Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene 33:403\u2013410","journal-title":"Oncogene"},{"key":"1764_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690","journal-title":"Nat Med"},{"key":"1764_CR5","doi-asserted-by":"publisher","first-page":"8361","DOI":"10.1074\/jbc.M111.286203","volume":"287","author":"P Christina","year":"2012","unstructured":"Christina P, Gordon JW, Saviz E, Mcdermott JC (2012) A novel RhoA\/ROCK-CPI-17-MEF2C signaling pathway regulates vascular smooth muscle cell gene expression. J Biol Chem 287:8361\u20138370","journal-title":"J Biol Chem"},{"key":"1764_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbcan.2018.05.007","volume":"1870","author":"E Di Giorgio","year":"2018","unstructured":"Di Giorgio E, Hancock WW, Brancolini C (2018) MEF2 and the tumorigenic process, hic sunt leones. Biochim Biophys Acta Rev Cancer 1870:261\u2013273","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1764_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pbiomolbio.2017.02.002","volume":"126","author":"C Dong","year":"2017","unstructured":"Dong C, Yang XZ, Zhang CY, Liu YY, Zhou RB, Cheng QD, Yan EK, Yin DC (2017) Myocyte enhancer factor 2C and its directly-interacting proteins: a review. Prog Biophys Mol Biol 126:22\u201330","journal-title":"Prog Biophys Mol Biol"},{"key":"1764_CR8","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-Cell non-hodgkin lymphoma. J Clin Oncol 33:2803\u20132811","journal-title":"J Clin Oncol"},{"key":"1764_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/386296a0","volume":"386","author":"J Han","year":"1997","unstructured":"Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ (1997) Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296\u2013299","journal-title":"Nature"},{"key":"1764_CR10","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.1093\/emboj\/16.23.7054","volume":"16","author":"Y Kato","year":"2014","unstructured":"Kato, Y., ., Kravchenko, V.V., Tapping, R.I., Han, J., Ulevitch, R.J., Lee, J.D. (2014). BMK1\/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16: 7054-7066.","journal-title":"EMBO J"},{"key":"1764_CR11","doi-asserted-by":"publisher","first-page":"17067","DOI":"10.1073\/pnas.0804868105","volume":"105","author":"D Khiem","year":"2008","unstructured":"Khiem D, Cyster JG, Schwarz JJ, Black BL (2008) A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc Natl Acad Sci U S A 105:17067\u201317072","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1764_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005845","volume":"12","author":"NR Kong","year":"2016","unstructured":"Kong NR, Davis M, Chai L, Winoto A, Tjian R (2016) MEF2C and EBF1 Co-regulate B cell-specific transcription. PLoS Genet 12:e1005845","journal-title":"PLoS Genet"},{"key":"1764_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-016-0364-0","volume":"9","author":"GS Laszlo","year":"2016","unstructured":"Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA (2016) Erratum to: high expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. J Hematol Oncol 9:133","journal-title":"J Hematol Oncol"},{"key":"1764_CR14","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Petar S, Lawrence MS, Daniel A, Bjoern C, Carrie S, Peter CG, Birgit K, Yan W, Asmann S, S.L. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109:3879\u20133884","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1764_CR15","doi-asserted-by":"publisher","first-page":"17199","DOI":"10.1074\/jbc.271.29.17199","volume":"271","author":"JD Molkentin","year":"1996","unstructured":"Molkentin, J.D., Li, L., ., Olson, E.N. (1996). Phosphorylation of the MADS-box transcription factor MEF2C enhances its DNA binding activity. J Biol Chem 271: 17199-17204.","journal-title":"J Biol Chem"},{"key":"1764_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/sj.leu.2405067","volume":"22","author":"S Nagel","year":"2008","unstructured":"Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, Macleod RAF (2008) MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia 22:600","journal-title":"Leukemia"},{"key":"1764_CR17","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","volume":"101","author":"M Nicolas","year":"2003","unstructured":"Nicolas M, Josette B, Christian G, Jean-Francois E, Pierre L, Catherine S, Francoise B, Andre B, Pierre M, Herve T (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279","journal-title":"Blood"},{"key":"1764_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","volume":"131","author":"L Pasqualucci","year":"2018","unstructured":"Pasqualucci L, Dalla-Favera R (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307\u20132319","journal-title":"Blood"},{"key":"1764_CR19","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.18632\/oncotarget.6223","volume":"7","author":"JR Pon","year":"2016","unstructured":"Pon JR, Marra MA (2016) MEF2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget 7:2297\u20132312","journal-title":"Oncotarget"},{"key":"1764_CR20","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/eji.200324127","volume":"33","author":"X Wei","year":"2003","unstructured":"Wei X, Sun W, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington T, Dakhama A, Lucas J, Johnson GL, Gelfand EW (2003) MEF2C regulates c-Jun but not TNF-alpha gene expression in stimulated mast cells. Eur J Immunol 33:2903\u20132909","journal-title":"Eur J Immunol"},{"key":"1764_CR21","first-page":"2498","volume":"106","author":"D Yang","year":"2005","unstructured":"Yang D, Spence SE, Jenkins NA, Copeland NG (2005) Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 106:2498\u20132505","journal-title":"Blood"},{"key":"1764_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ni.2688","volume":"14","author":"CY Ying","year":"2013","unstructured":"Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Hussein S, Bansal M, Califano A, Pasqualucci L, Basso K, Dalla-Favera R (2013) MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol 14:1084\u20131092","journal-title":"Nat Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01764-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:26:09Z","timestamp":1609547169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01764-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Patients were diagnosed according to the criteria of the World Health Organization classification of hematological malignancies. Before the initiation of treatment, the clinical features, including Mantle Cell Lymphoma International Prognostic Index (MIPI) score, lactate dehydrogenase (LDH) content in serum, performance status (determined using Eastern Cooperative Oncology Group performance status scores) and white blood cell (WBC) counts, were collected. All experimental protocols and procedures involved in the present study were approved by the Ethics Committee of the First People's Hospital of Lianyungang. Written informed consent was obtained from all participates for publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}